江龙光
日期:2021-06-08 阅读次数: 作者: 来源:


姓    名:江龙光
性    别:
职    称:副教授
学    历:博士
职    务:化学生物学与制药工程系副主任
电    话:0591-22867972
专    业:生物化学与分子生物学
电子邮件:jianglg@fzu.edu.cn
研究方向:化学生物学、结构生物学


教育工作经历

2016.02 – 至今:福州大学化学学院

2018.10-2019.10 哈佛医学院,访问学者

(合作导师:Prof. Robert C. Flaumenhaft, MD, PhD

2010.7 - 2016.1: 中国科学院福建物质结构研究所,助理研究员

2014.7 - 2014.10: 丹麦奥胡斯大学,访问学者

(合作导师:Prof. Peter A. Andreasen, PhD

2005.9 - 2010.7: 中国科学院福建物质结构研究所,博士

(导师:黄明东 研究员)

2001.9 - 2005.7: 贵州大学,学士


教学简介

《生物化学》、《制药工程专业英语》、《综合化学实验》和《制药工程创新创业实践》


科研简介

长期围绕内皮与凝血和纤溶系统,通过生物化学、分子生物学、生物物理学等手段,开展相关蛋白(凝血因子VII、XI、尿激酶及其受体、血浆激肽酶、PECAM-1、Ang/Tie)及其配体的结构和功能研究。作为项目负责人承担多项国家自然科学基金,福建省自然科学基金及技术转化项目等课题,并以第一作者或通讯作者发表SCI论文20余篇,参编1部专著,获授权专利3项。

  

社会兼职

福建省生物工程学会,理事


科研项目

1. Ang1/Tie2轴在脓毒症DIC中调控血栓形成和维持血管内皮细胞稳态的分子机制研究(82070142),国家自然科学基金面上项目,2021-2024,项目负责人

2. 医学转化研究,企业横向项目,2020-2023,项目负责人

3. 凝血和纤溶中的新机理和新疗法(2017YFE0103200),国家重点研发计划项目,2018-2021,研究骨干

4. 关键蛋白酶的结构研究及基于结构的抑制剂理性设计与改造(2018J01729),福建省科技厅面上项目,2018-2021,项目负责人 

5. 血小板内皮细胞黏附分子-1的结构研究(31400637),国家自然科学基金青年项目,2015-2017,项目负责人 

6. 抑制肿瘤转移的尿激酶多肽抑制剂的结构生物学研究(2012J05071),福建省科技厅青年创新项目,2012-2015,项目负责人 


代表性论文 

26 Sun G, Yang M, Jiang L#Huang M#. Regulation of pro-σK activation: a key checkpoint in Bacillus subtilis sporulation. Environ Microbiol. 2021 Feb 4. doi: 10.1111/1462-2920.15415. Epub ahead of print. (#: co-corresponding authors)

25 Jiang L, Yuan C, Huang M. A general strategy to inhibit serine protease by targeting its autolysis loop. FASEB J. 2021 Feb;35(2):e21259. doi: 10.1096/fj.202002139RR. (#: co-corresponding authors) 

24. Yuan C, Guo Z, Yu S, Jiang L#, Huang M#. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today. 2021 Jan 21:S1359-6446(21)00045-3. doi: 10.1016/j.drudis.2021.01.016. Epub ahead of print. (#: co-corresponding authors)

23. Huang M, Li L, Shen J, Wang Y, Wang R, Yuan C, Huang M#Jiang L#. Plasma levels of the active form of suPAR are associated with COVID-19 severity. Crit Care. 2020 Dec 29;24(1):704. (#: co-corresponding authors)

22. 王蕊,黄美娟,许燕艳,袁彩,黄明东,江龙光Ang-Tie轴在血管和淋巴系统相关疾病中作用的研究进展,生物工程学报2020,已接受.

21. Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M#, Jiang L#, Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA, RSC Adv., 2020,10, 34517-34526. (#: co-corresponding authors)

20. G Xue, X Xie, Y Zhou, C Yuan, M Huang#, Jiang L#. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases. Biosci Biotechnol Biochem. 2020 Jun;84(6):1153-1159. (#: co-corresponding authors)

19. Xie X, Guo N, Xue, Xie D, Yuan C, Harrison J, Li J, L. Jiang L#, Huang M#. Solution structure of SpolVB reveals mechanism of PDZ domain-regulated protease activity. Frontiers in Microbiology2019, 10, 1232.

18. Jiang J, Xie X, Li J, Persson E, Huang M. Crystal structure, epitope and functional impact of an antibody against a super-active FVIIa provide insights into allosteric mechanism. Research and Practice in Thrombosis & Haemostasis2019, doi: 10.1002/rth2.12211.

17. Jiang L, Zhang X, Zhou Y, Chen , Luo Z,  Li J, Yuan C, Huang M. Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. RSC Advances2018, 8, 28189.

16. Jiang L, Oldenburg E, Kromann-Hansen T, Xu P, Jensen JK, Andreasen PA, Huang M. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition. Biochim Biophys Acta. 2018, Jun 26. pii: S0304-4165(18)30180-6.

15. Sun YG*, Li R*, Jiang L*, Qiao S, Zhi Y, Chen XX, Xie S, Wu J, Li X, Deng R, Zhang G. Characterization of the interaction between recombinant porcine aminopeptidase N and spike glycoprotein of porcine epidemic diarrhea virus. Int J Biol Macromol. 2018, May 24; 117:704-712. (*: Equal contributions).

14. Xie X, Xue G, Jiang L#, Huang M#. Ligand Induced Conformational Transitions of Tissue Factor Ω loop, Chinese J. Struct. Chem. 2018, 37(6), 961-968. (#: co-corresponding authors)

13. Xu M, Chen Y, Xu P, Andreasen PA, Jiang L#, Li J#, Huang M#. Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217. FEBS Lett. 2018 Aug;592(15):2658-2667. (#: co-corresponding authors)

12. Xu M, Xu P, Zhou X, Andreasen PA, Jiang L#, Huang M#. Crystal structures of the serine protease domain of murine plasma kallikrein, Chinese J. Struct. Chem. 2017, 36(2), 961-968. (#: co-corresponding authors)

11. Xue G, Gong L, Yuan C, Xu M, Wang X, Jiang L#, Huang M. A structural mechanism of flavonoids in inhibiting serine proteases. Food Funct. 2017 Jul 19;8(7):2437-2443. (#: co-corresponding authors)

10. Ma H, Qiao S, Huang M, Jiang L#, Li R#, Zhang G#. Crystal Structure of a CD163 Scavenger Receptor Cysteine-rich Domain Produced in Pichia PastorisChinese J. Struct. Chem. 2017, 36(9), 961-968. (#: co-corresponding authors)

9. Ma H*, Jiang L*, Qiao S, Zhi Y, Chen XX, Yang Y, Huang X, Huang M, Li R, Zhang GP. Crystal Structure of the Fifth Scavenger Receptor Cysteine-Rich Domain (SRCR5) from Porcine CD163 Reveals an Important Residue Involved in Porcine Reproductive and Respiratory Syndrome Virus Infection. J Virol. 2017 Jan 18;91(3). pii: e01897-16. (*: Equal contributions)

8. Jiang L, Lin L, Li R, Yuan C, Xu M, Huang JH, Huang M. Dimer conformation of soluble PECAM-1, an endothelial marker. Int J Biochem Cell Biol. 2016 Jun 3;77 (Pt A):102-108.

7. Jiang L, Andersen LM, Andreasen PA, Chen L, Huang M. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate. Biochim Biophys Acta-General subjects. 2016 Mar; 1860 (3):599-606.

6. Jiang L, Zhao B, Xu P, Sørensen HP, Jensen JK, Christensen A, Hosseini M, Nielsen NC, Jensen KJ, Andreasen PA, Huang M. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues. Int J Biochem Cell Biol. 2015 May; 62:88-92.

5. Jiang L, Botkjaer KA, Andersen LM, Yuan C, Andreasen PA, Huang M. Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J. 2013 Jan 1; 449 (1): 161-6.

4. Jiang L*, Svane AS*, Sørensen HP, Jensen JK, Hosseini M, Chen Z, Weydert C, Nielsen JT, Christensen A, Yuan C, Jensen KJ, Nielsen NC, Malmendal A, Huang M, Andreasen PA. The Binding Mechanism of a Peptidic Cyclic Serine Protease Inhibitor. J Mol Biol. 2011 412(2), 235-50. (*: Equal contributions).

3. Jiang L, Yuan, C, Chen, H, Wang, Y, Zhao, B, Zhang, X, and Huang, M, Preparation and structure of a new coagulation factor XI catalytic domain for drug discovery. Chinese J. Struct. Chem. 2011, 30 (7), 1021-59.

2. Jiang L, Zhao G, Bian C, Yuan C, Huang Z, Huang M. Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol. Chinese J. Struct. Chem. 200928(2), pp. 253-259.

1. Jiang, L, Yu H, Yuan C, Wang J, Chen L, Edward J. Meehan, Huang Z, Huang M. The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator. Chinese J. Struct. Chem. 2009, 28(11):1427-1432.


获奖情况

 2020年度“鸿耀奖教奖”


其他

专著

1. Iqbal Z, Jiang L, Chen Z, Yuan C, Li R, Zheng K, Zhou X, Chen J, Hu P, Huang M (2017) Tumor specific imaging and photodynamic therapy targeting on urokinase receptor, chapter 13, page 259-274. In “Imaging in Photodynamic Therapy” Edited by Michael R. Hamblin and Yingying Huang, Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742 CRC Press 2017